Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis
Tricco AC, Blondal E, Veroniki AA, Soobiah C, Vafaei A, Ivory J, Strifler L, Cardoso R, Reynen E, Nincic V. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis. BMC Medicine. 2016;14(1):216. DOI: 10.1186/s12916-016-0761-9
Altmetric:
Bottom Line:
- An assessment of the comparative safety of serotonin (5-HT3) receptor antagonists found that these agents were relatively safe, although none of the included studies evaluated active treatment with placebo for harms
- All agents were effective in reducing the risk of nausea, vomiting, and chemotherapy-induced nausea or vomiting
Impact:
- Our results can be used by patients and physicians to tailor administration of these agents
- Provided Health Canada with evidence on the safety and effectiveness of these agents for their decision-making
Protocol:
Additional Resources:
Funding:
Canadian Institutes of Health Research (CIHR)/ Drug Safety and Effectiveness Network (DSEN)
Comparative efficacy of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis
Tricco AC, Soobiah C, Blondal E, Veroniki AA, Khan PA, Vafaei A, Ivory J, Strifler L, Ashoor H, MacDonald H, Reynen E, Robson R, Ho J, Ng C, Antony J, Mrklas K, Hutton B, Hemmelgarn BR, Moher D, Straus SE. Comparative efficacy of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis. BMC Med. 2015;13:136. DOI: 10.1186/s12916-015-0371-y
Altmetric:
Bottom Line:
- Granisetron plus dexamethasone was often the most effective agent at reducing nausea in patients undergoing surgery among the compared serotonin (5-HT3) receptor antagonists
- The number of patients needed to treat ranged from two to five
Impact:
- Our results can be used by patients and physicians to tailor administration of these agents
- Provided Health Canada with evidence on the efficacy of these agents for their decision-making
- Featured in >30 mass media articles
Protocol:
Additional Resources:
Funding:
Canadian Institutes of Health Research (CIHR)/ Drug Safety and Effectiveness Network (DSEN)
Comparative safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis
Tricco AC, Soobiah C, Blondal E, Veroniki AA, Khan PA, Vafaei A, Ivory J, Strifler L, Ashoor H, MacDonald H, Reynen E, Robson R, Ho J, Ng C, Antony J, Mrklas K, Hutton B, Hemmelgarn BR, Moher D, Straus SE. Comparative safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis. BMC Med. 2015;13:142. DOI: 10.1186/s12916-015-0379-3
Altmetric:
Bottom Line:
- Granisetron plus dexamethasone increased the risk for arrhythmia in patients undergoing surgery among the compared serotonin (5-HT3) receptor antagonists
- However, the included studies in this analysis did not consistently report harms when assessing for the safety of these agents
Impact:
- Our results can be used by patients and physicians to tailor administration of these agents
- Provided Health Canada with evidence on the safety of these agents for their decision-making
- Featured in >30 mass media articles
Protocol:
Additional Resources:
Funding:
Canadian Institutes of Health Research (CIHR)/ Drug Safety and Effectiveness Network (DSEN)
Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review
Tricco AC, Soobiah C, Hui W, Antony J, Struchkov V, Hutton B, Hemmelgarn B, Moher D, Straus SE. Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review. BMC Pharmacol Toxicol. 2015;16:1. DOI: 10.1186/2050-6511-16-1
Altmetric:
Bottom Line:
- ECG monitoring of chemotherapy patients administered with serotonin (5-HT3) receptor antagonists did not reveal clinically significant differences in arrhythmia between the medications at the examined time periods
Impact:
- Provided Health Canada with evidence on the safety of these agents for their decision-making
Protocol:
Additional Resources:
Canadian Institutes of Health Research (CIHR)/Drug Safety and Effectiveness Network (DSEN)
Category : KS Projects
Date : 24 Aug 2017